AC Immune SA (ACIU): Price and Financial Metrics


AC Immune SA (ACIU)

Today's Latest Price: $7.39 USD

0.35 (-4.52%)

Updated Jun 1 6:55pm

Add ACIU to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ACIU Stock Summary

  • For ACIU, its debt to operating expenses ratio is greater than that reported by merely 7.68% of US equities we're observing.
  • With a year-over-year growth in debt of 518.33%, AC Immune SA's debt growth rate surpasses 96.5% of about US stocks.
  • Revenue growth over the past 12 months for AC Immune SA comes in at 186.99%, a number that bests 96.62% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AC Immune SA are ETTX, ERYP, CLDX, UMRX, and ORMP.
  • Visit ACIU's SEC page to see the company's official filings. To visit the company's web site, go to www.acimmune.com.
ACIU Daily Price Range
ACIU 52-Week Price Range

ACIU Stock Price Chart More Charts


ACIU Price/Volume Stats

Current price $7.39 52-week high $10.14
Prev. close $7.74 52-week low $4.07
Day low $7.38 Volume 71,400
Day high $7.73 Avg. volume 143,186
50-day MA $7.26 Dividend yield N/A
200-day MA $6.96 Market Cap 499.28M

AC Immune SA (ACIU) Company Bio


AC Immune SA, a clinical stage Swiss-based biopharmaceutical company, focuses on neurodegenerative diseases with three product candidates in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by mis-folding proteins. The company was founded in 2003 and is based in Lausanne, Switzerland.

ACIU Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$7.39$8.084%

We started the process of determining a valid price forecast for AC Immune SA with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that AC Immune SA ranked in the 48th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 4.5%. In terms of the factors that were most noteworthy in this DCF analysis for ACIU, they are:

  • The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately only 3.73% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • AC Immune SA's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%2%
1%3%
2%4%
3%5%
4%6%
5%7%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ACIU, try HCSG, LH, HSIC, EDAP, and GILD.


ACIU Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ACIU Latest Social Stream


Loading social stream, please wait...

View Full ACIU Social Stream

Latest ACIU News From Around the Web

Below are the latest news stories about AC Immune SA that investors may wish to consider to help them evaluate ACIU as an investment opportunity.

AC Immune CEO to Showcase Novel Target Programs at UBS Global Healthcare Conference

LAUSANNE, Switzerland, May 15, 2020 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.

Yahoo | May 15, 2020

AC Immune SA (NASDAQ:ACIU) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

As you might know, AC Immune SA (NASDAQ:ACIU) just kicked off its latest quarterly results with some very strong...

Yahoo | May 6, 2020

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research | May 4, 2020

AC Immune Reports Q1 2020 Financial Results and Provides Business Update

On track to meet the five clinical milestones expected in 2020 with no modifying guidance as a result of Covid-19Ongoing strong financial position with CHF 277.9 million in.

Yahoo | May 4, 2020

Axsome Shares Jump 25% on Alzheimer's Study Results

Clinical trial of AX-05 showed drug reduces patient agitation Continue reading...

Yahoo | April 28, 2020

Read More 'ACIU' Stories Here

ACIU Price Returns

1-mo 8.36%
3-mo 2.07%
6-mo -9.77%
1-year 47.50%
3-year -16.40%
5-year N/A
YTD -13.26%
2019 -9.84%
2018 -26.17%
2017 -1.39%
2016 N/A
2015 N/A

Continue Researching ACIU

Want to see what other sources are saying about AC Immune SA's financials and stock price? Try the links below:

AC Immune SA (ACIU) Stock Price | Nasdaq
AC Immune SA (ACIU) Stock Quote, History and News - Yahoo Finance
AC Immune SA (ACIU) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.2532 seconds.